YKYoshinobu Komai

Yoshinobu Komai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshinobu Komai has a total of 146 co-authors. Here are the top co-authors by number of shared publications:

  • Junji Yonese

    Department of Urology, Canter Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

    9 shared publications
  • Noboru Numao

    Department of Genitourinary Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan

    7 shared publications
  • Shinya Yamamoto

    Department of Urology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan

    7 shared publications
  • Ryo Fujiwara

    Department of Genitourinary Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

    6 shared publications
  • Satoru Kawakami

    Department of Urology, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan

    6 shared publications
  • Shinya Yamamoto

    Department of Urology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan

    6 shared publications

Latest Publications

  • Development of a New Two-Arm Transurethral Surgical System for En Bloc Resection of Bladder Tumor: A Preclinical Study

    by Yoshinobu Komai, Kunihiko Nakajima, Kyosuke Saito, Yutaka Tomioka, Hitoshi Masuda, Akira Ogawa, Junji Yonese, Etsuko Kobayashi, Masaaki Ito

    Backgrounds and Objectives: To overcome the piecemeal nature of bladder tumor resection, en bloc resection of bladder tumor (ERBT) has been introduced. ERBT is difficult for surgeons to perform using the currently available system because it has only one arm. Herein, we aimed to develop a new transurethral surgical system to facilitate two-arm ERBT and to report the results of preclinical experiments using tumor phantoms. Methods: Initially, we aimed to develop a brand-new surgical system for ERBT but, after trial and error, we redirected our development to the creation of three elements: the left arm to grasp the tumor; the right arm to cut the tumor; and the system to operate the arms that can be attached to the existing surgical system (UES-40 SurgMaster ® [Olympus Co. Ltd., Tokyo, Japan]). The current system was evaluated by performing simulated ERBTs using tumor phantoms made from konjac jelly. Results: Following the assembly of developed arms into the UES-40 SurgMaster, we conducted preliminary ERBTs. After performing several resections, we adopted a basket-shaped forceps as the left arm instead of grasping forceps and an arched electrode as the right arm. The two arms and single endoscope were placed in an equilateral triangle. We performed ERBT for the tumor phantoms that ranged from 0.5 to 2.0 cm without major redo. Conclusion: Herein, we introduced our development for two-arm ERBT. The current concept of “two-hand transurethral surgery” has the potential to be developed in future in vivo and clinical trials.


  • Renal function outcome after selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and consolidative partial cystectomy in comparison with radical cystectomy for patients with muscle-invasive bladder cancer: a two-centre retrospective study

    by Motohiro Fujiwara, Minato Yokoyama, Masahiro Toide, Ryo Fujiwara, Hajime Tanaka, Tomohiko Oguchi, Yoshinobu Komai, Soichiro Yoshida, Yoh Matsuoka, Noboru Numao, et al.

    To compare renal function (RF) outcomes after bladder-preserving tetramodal therapy against muscle-invasive bladder cancer (MIBC) to those after radical cystectomy (RC). This study included 95 patients treated with tetramodal therapy consisting of transurethral bladder tumour resection, chemoradiotherapy and partial cystectomy (PC) and 300 patients treated with RC. The annual change in the estimated glomerular filtration rate (eGFR) was compared using the linear mixed model. Renal impairment was defined as a >25% decrease from the pretreatment eGFR, and renal impairment-free survival (RIFS) was calculated. The association between treatment type and renal impairment was assessed. The number of patients who received neoadjuvant chemotherapy was 8 (8.4%) in the tetramodal therapy group and 75 (25.0%) in the RC group. After the inverse probability of treatment weighting adjustments, the baseline characteristics were balanced between the treatment groups. The mean eGFR before treatment in tetramodal therapy and RC groups was 69.4 and 69.6 mL/min/1.73 m2 and declined with a slope of −0.7 and −1.5 mL/min/1.73 m2/year, respectively. The annual deterioration rate of post-treatment eGFR in the tetramodal therapy group was milder than in the RC group. The 5-year RIFS rate in the tetramodal therapy and the RC groups was 91.2 and 85.2%, respectively. Tetramodal therapy was an independent factor of better RIFS compared with RC. RF was better preserved after tetramodal therapy than after radical therapy; however, even after tetramodal therapy, the eGFR decreased, and a non-negligible proportion of patients developed renal impairment.


  • Tumor shrinkage patterns of nivolumab monotherapy in metastatic renal cell carcinoma

    by Kosuke Hamada, Ryo Fujiwara, Kosuke Takemura, Yoshinobu Komai, Tomohiko Oguchi, Noboru Numao, Shinya Yamamoto, Junji Yonese, Takeshi Yuasa

    Objectives: To investigate the tumor shrinkage patterns of patients with metastatic renal cell carcinoma treated with nivolumab monotherapy.Methods: Forty‐four consecutive patients with metastatic renal cell carcinoma treated with nivolumab monotherapy (81 metastatic and four primary lesions) between September 2013 and December 2020 were retrospectively analyzed. The tumor shrinkage rate of individual visceral and lymph node metastatic lesions and the primary site lesions treated with nivolumab monotherapy, as well as the association between overall survival and pretreatment tumor size, were statistically assessed.Results: Pretreatment tumor size for the total and individual target lesions, which included kidneys, lungs, pancreas, and lymph nodes, were not correlated with tumor shrinkage rate. The tumor shrinkage rate was found to have no significant association with pretreatment tumor size between any organ. In addition, there is no significant difference in tumor shrinkage rate between larger (>median value) and smaller (<median value) pretreatment tumor size in any organ. Finally, there was no significant difference in overall survival between larger and smaller pretreatment tumor size.Conclusions: Pretreatment tumor size was not associated with the tumor shrinkage rate and overall survival in nivolumab monotherapy.

  • Intra‐ and post‐operative management of pancreatic injury during laparoscopic nephrectomy

    by Jun Miki, Takeshi Yamasaki, Yoshinobu Komai, Toru Kanno, Kojiro Ohba, Takeyuki Misawa, the Jikei‐Kyoto‐Osaka‐Nagasaki‐Ganken Group (J‐KONG Group)


  • Improving Accuracy, Reliability, and Efficiency of the RENAL Nephrometry Score With 3D Reconstructed Virtual Imaging

    by Kasumi Kaneko Yoshitomi, Yoshinobu Komai, Tatsuya Yamamoto, Eri Fukagawa, Kosuke Hamada, Yusuke Yoneoka, Motohiro Fujiwara, Ryo Fujiwara, Tomohiko Oguchi, Noboru Numao, et al.


  • Open Access

    Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single‐center analysis in Japan

    by Motohiro Fujiwara, Takeshi Yuasa, Tetsuya Urasaki, Yoshinobu Komai, Ryo Fujiwara, Noboru Numao, Shinya Yamamoto, Junji Yonese

    Background: The paradigm of medical treatment for metastatic urothelial carcinoma is dramatically changing through the introduction of pembrolizumab.Aim: We investigated the treatment effectiveness, the safety profile, and the prognostic factors of pembrolizumab in Japanese real‐world clinical practice.Methods and results: The medical records of 74 consecutive Japanese patients with metastatic urothelial cancer (UC), who started pembrolizumab as a second‐ or later‐line treatment at our institution between January 2018 and March 2020, were reviewed and statistically analyzed. The median follow‐up period after initiation of pembrolizumab was 8.5 (interquartile range: 3.5–15.7) months. The objective response rate was 30.2%, the median progression‐free survival period was 4.9 months, and the median overall survival (OS) period was 13.3 months. Evaluation revealed that 39 (52.9%) patients experienced adverse events (AEs), among whom eight patients (10.9%) had severe AEs (grade 3 or more), including grade 5 hemophagocytic syndrome. Multivariate analysis indicated that the presence of liver metastasis, worse performance status (≥2), elevated serum lactate dehydrogenase, and increased C‐reactive protein were predictive of shorter OS.Conclusion: We studied the effectiveness and safety profile of pembrolizumab therapy in Japanese UC patients. We believe that the data presented here will be useful for clinical physicians.


  • Open Access

    Case Report: A Case of Trimethoprim/Sulfamethoxazole-Triggered Hypotensive Shock: Cytokine Release Syndrome Related to Immune Checkpoint Inhibitors and Drug-Induced Hypersensitivity Syndrome

    by Tetsuya Urasaki, Makiko Ono, Toshiaki Mochizuki, Koichi Takeda, Aya Nishizawa, Eri Fukagawa, Motohiro Fujiwara, Yoshinobu Komai, Shigehisa Kitano, Takeshi Yuasa, et al.

    Currently, only a few reports exist on the cytokine release syndrome (CRS) as one of the severe immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs). Notably, it is very rare that grade 4 CRS related to ICI therapy overlaps with the drug-induced hypersensitivity syndrome (DiHS). A 46-year old woman with metastatic kidney cancer had grade 3 interstitial pneumonitis induced by four cycles of combination therapy of anti-programmed death-1 and anti-cytotoxic T lymphocyte-4 antibodies after right cytoreductive nephrectomy. Prophylactic administration of trimethoprim/sulfamethoxazole (TMP/SMX) was started concomitantly with prednisolone therapy to treat the interstitial pneumonitis. She developed hypotensive shock when reducing the dosage of prednisolone, and required intubation and ventilation using vasopressors at the intensive care unit. She subsequently exhibited prominent leukocytosis and an increased level of C-reactive protein, suggesting markedly increased cytokine levels. Interestingly, facial edema and erythema increased in association with pyrexia, leukocytosis, liver dysfunction, and renal failure, suggesting that she developed DiHS. She received hemodialysis three times, a plasma exchange, and anti-interleukin-6 therapy to treat severe renal dysfunction, a thrombotic thrombocytopenic purpura-suspected condition, and possible grade 4 CRS, respectively. Although these therapies did not elicit sufficient effects, high-dose administration of intravenous immunoglobulin was successful. With steroid mini-pulse therapy and the subsequent administration of prednisolone, she recovered successfully. To the best of our knowledge, this is the first report that ICIs and TMP/SMX can induce hypotensive shock accompanied with CRS and DiHS during immunosuppressive therapy for an irAE. Importantly, the prophylactic administration of TMP/SMX should be performed cautiously to avoid severe drug reactions such as CRS or DiHS.


  • “Crush Carving Technique” Using a Soft Coagulation Device: A Simple Method for Successful Laparoscopic Partial Nephrectomy Without Hilar Clamping

    by Yoshinobu Komai, Kosuke Hamada, Motohiro Fujiwara, Kasumi Kaneko Yoshitomi, Yudai Ishikawa, Eri Fukagawa, Ryo Fujiwara, Tomohiko Oguchi, Noboru Numao, Takeshi Yuasa, et al.

    Introduction: According to recent studies, kidney parenchymal volume preservation was significantly associated with ultimate renal function than hilar clamping in partial nephrectomy (PN) cases.1,2 Off-clamp PN, however, has a role for chronic kidney disease (CKD) patients, the number of which has been rising.3 We herein describe our new method called “crush carving technique” in laparoscopic PN without hilar clamping. Materials and Methods: By using a unique output mode called “soft coagulation,”4 we have developed a simple and novel method that can achieve both of bloodless operative field and minimal hilar clamping time during laparoscopic PN. The soft coagulation mode can automatically regulate output voltage and the kidney parenchyma can be effectively dissected according to a surgeon's planning with excellent hemostasis even without hilar clamping. Tumor resection was performed as follows: (1) the incision line was determined using intraoperative ultrasound guidance; (2) with a 0.5- to 1-cm margin from the tumor edge, we placed shallow incision of the depth within the renal cortex; (3) the deeper parenchymal area was dissected using crush carving technique with the use of a ball-shaped soft coagulation device, and the tumor was completely excised. In this study, we focused on pre-existing CKD (≥stage 3a) patients because not only remnant renal parenchyma but also reduced ischemia time appears to have a role for functional outcomes. Results: This case series included six patients who had an imperative indication for PN because of stage 3a CKD as a comorbidity. All patients had a complex tumor of R.E.N.A.L. nephrometry score ≥8. All surgeries using the current technique were effectively completed by a single surgeon (Y.K.) without hilar clamping with satisfactory perioperative outcomes. Decrease in estimated glomerular filtration rate was minimal and progression of CKD stage was not observed in any case. Conclusion: We present our new method called “crush carving technique,” which can provide both effective dissection and bloodless field in laparoscopic PN. The current technique may be useful especially in patients with pre-existing CKD. Acknowledgments: We thank Ms. Kyoko Komai for the narration of this video. No competing financial interests exit. Runtime of video: 6 mins 58 secs